What are dental implants and how does Nobel Biocare compete in the market?

Dental implants are titanium posts surgically placed into the jawbone to replace the root of a missing tooth — a permanent solution to tooth loss compared to dentures or dental bridges. The implant procedure: an oral surgeon or periodontist places the titanium implant into the jawbone; after 3-6 months of osseointegration (bone fusing to the implant), a crown (prosthetic tooth) is attached via an abutment; the result is a tooth replacement that looks and functions like a natural tooth; implants can last a lifetime with proper care. The dental implant market: global dental implant market is approximately $5-6B annually; major competitors include Straumann (Swiss, approximately 25% global share), Nobel Biocare/Envista (approximately 15-18%), Zimmer Biomet Dental (approximately 10%), Dentsply Sirona (approximately 10%), and dozens of other regional and value-tier brands. Nobel Biocare positioning: Nobel Biocare (founded 1981, Swedish company, acquired by Danaher in 2014, now part of Envista) is the original commercial dental implant company; Nobel Biocare's Branemark implant system was the first commercially successful osseointegrating implant (per-Henrik Branemark research); Nobel Biocare competes in the premium implant segment targeting specialists (oral surgeons, periodontists, prosthodontists) with premium-priced implants supported by the most extensive clinical literature of any implant brand.

What is the GLP-1 drug boom and why does it benefit Stevanato?

GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists) are a class of drugs originally developed for type 2 diabetes that also cause significant weight loss — the most commercially successful drugs in history. Key GLP-1 drugs: Ozempic/Wegovy (semaglutide, Novo Nordisk) — semaglutide is approved for diabetes (Ozempic) and weight loss (Wegovy); injected once weekly via a prefilled pen; Wegovy generates approximately $5-7B in annual revenue and growing rapidly. Mounjaro/Zepbound (tirzepatide, Eli Lilly) — dual GLP-1/GIP agonist showing even greater weight loss than semaglutide; injected weekly; tirzepatide sales growing to rival semaglutide. The GLP-1 supply challenge: both Novo Nordisk and Eli Lilly have struggled to manufacture sufficient quantities of their GLP-1 drugs to meet demand; the bottleneck includes drug synthesis capacity and drug packaging capacity (prefillable pens, cartridges, autoinjectors — each filled weekly for millions of patients). Why Stevanato benefits: each GLP-1 dose is administered via a prefilled pen or autoinjector that requires a cartridge or syringe manufactured by companies like Stevanato; weekly dosing means approximately 50 doses per patient per year; if 50 million people globally are on GLP-1 drugs (a realistic medium-term projection), that's 2.5 billion containers per year; Stevanato has signed significant supply agreements with major GLP-1 manufacturers and is building capacity to serve this demand; this is potentially the most impactful growth driver in pharmaceutical packaging history.

What is Invisalign and how does Spark (Ormco) compete with it?

Invisalign is a clear aligner orthodontic treatment system developed by Align Technology — custom-made transparent plastic trays that gradually move teeth into correct position, worn 20-22 hours per day and changed every 1-2 weeks. Align Technology's market dominance: Align Technology pioneered commercial clear aligners in 1997; Invisalign represents approximately 80% of the clear aligner market by revenue; Align's advantages include: the largest clinical database of treated cases (over 14 million patients), the iTero intraoral scanner integrated with treatment planning, extensive orthodontist and general dentist training programs, and strong brand recognition among patients who specifically request Invisalign. Spark clear aligners (Ormco/Envista): Ormco is a traditional orthodontic bracket and wire company (part of Envista) that entered the clear aligner market with Spark; Spark's differentiation: TruGEN XR material is claimed to be clearer than Invisalign (important for patient aesthetics) and more comfortable due to edge smoothness; Spark targets orthodontists specifically (not general dentists), focusing on complex cases where orthodontists' expertise creates higher clinical demand. Competitive dynamics: competing with Invisalign requires matching Align's treatment planning technology, clinical outcome data, and doctor training ecosystem; Spark has achieved meaningful adoption among orthodontists who prefer having an alternative to Invisalign's market dominance; however, overcoming Align's network effects (doctors trained on Invisalign workflow and iTero scanners) is the fundamental commercial challenge.

brimindinvest.com / compare / stvn-vs-nvstLIVE

STVN

Stevanato Group S.p.A. · Healthcare - Drug Containment & Delivery Systems

$17.54

+1.58% this month

VERSUS

⟷

COMPARE

NVST

Envista Holdings Corporation · Healthcare - Dental Products & Technology

$25.91

+12.41% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

STVN

1

NVST

3

NVST LEADS 3/5

Comparison scoreboard

NVST LEADS 3/5

AI Score

STVN 22.7

NVST ✓23.9

1Y Return

STVN -25.88%

NVST ✓+39.23%

Fwd P/E

STVN 20.93

NVST ✓15.65

Target Up.

STVN ✓+39.40%

NVST +20.70%

Op. Margin

STVN N/A

NVST 9.87%

Metrics last refreshed: 6/20/2026

Quick take

STVN vs NVST Stock Comparison: AI Score, Valuation, Performance and Upside

STVN (Stevanato Group) and NVST (Envista Holdings) are both global healthcare companies with differentiated product portfolios in different healthcare subsectors — Stevanato provides pharmaceutical drug containment solutions (glass vials, syringes, polymer containers) benefiting from biologic and GLP-1 drug growth, while Envista provides dental products (Nobel Biocare implants, Spark clear aligners, Kerr materials, DEXIS imaging) across the full dental product spectrum. Both have specific near-term growth drivers and competitive challenges.

STVN vs NVST is pharmaceutical drug containment and delivery systems with GLP-1 tailwind (Stevanato's glass vials, prefillable syringes, and cartridges serving biologic drug and GLP-1 injectable growth with high-value product mix shift improving margins) versus diversified dental products company post-Danaher spinoff (Envista's Nobel Biocare implants, Spark aligners, and DEXIS imaging equipment navigating competitive dental implant market and challenging Invisalign in clear aligners) — pharma packaging infrastructure versus dental product portfolio breadth.

Live analysis · updated 6/20/2026

NVST holds the edge across 3 of 5 key metrics in this comparison. NVST leads on both 1-year return (+39.23%) and forward P/E (15.65x vs 20.93x for STVN), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for STVN (+39.40%) than for NVST (+20.70%).

Normalized 1Y performance

STVN

NVST

Recent returns

STVN

NVST

Analyst price targets & sentiment

STVN · 10 analysts

STRONG BUYHOLDSTRONG SELL

Buy (1.5/5.0)

Price target range

analyst low$17.50
analyst high$32.00
analyst mean$24.45
current price$17.54

+39.4% upside to analyst mean

NVST · 12 analysts

STRONG BUYHOLDSTRONG SELL

Hold (2.6/5.0)

Price target range

analyst low$15.00
analyst mean$29.69
current price$25.91

+20.7% upside to analyst mean

Who should consider this stock?

STVN may suit investors who:

→Believe the GLP-1 drug boom (Ozempic, Wegovy, Mounjaro, Zepbound) will drive exceptional demand for prefillable pens, cartridges, and syringes for years as these drugs become the most prescribed injectable drugs globally
→Value Stevanato's position as a critical supplier to the pharmaceutical industry providing drug containment infrastructure that every injectable drug needs regardless of which specific drug wins the market
→See Stevanato's high-value product mix shift (toward premium prefillable syringes and coated vials) as a margin improvement driver as commodity glass vial revenue grows more slowly than specialty containers

NVST may suit investors who:

→Value Nobel Biocare's premium dental implant brand and multi-decade clinical data as providing durable market position in the premium dental implant segment against increasing price competition
→Believe Envista's margin improvement opportunity post-Danaher spin-off will be realized as the company rationalizes its portfolio and improves operational efficiency without the parent company's conglomerate overhead
→See Spark clear aligners (Ormco) as gaining share in the rapidly growing clear aligner market against Invisalign's dominant position, particularly among orthodontists looking for alternative clear aligner systems

Performance & AI score

Metric	STVN	NVST
AI score	22.7	23.9
AI rank	#3949	#3380
Latest close	$17.54	$25.91
1M return	+1.58%	+12.41%
6M return	-15.21%	+18.58%
1Y return	-25.88%	+39.23%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

Period	STVN	NVST
1Y ago	$7.44K (-25.6%) started 2025-06-18	$13.92K (+39.2%) started 2025-06-18
5Y ago	$9.19K (-8.1%) started 2021-07-16	$6.06K (-39.4%) started 2021-06-18
10Y ago	$9.19K (-8.1%) started 2021-07-16	$9.27K (-7.3%) started 2019-09-18

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Metric	STVN	NVST
Market cap	$4.79B	$4B
Trailing P/E	29.73	60.00
Forward P/E	20.93	15.65
Price/Sales	3.98	1.27
EV/Revenue	4.03	1.61
Analyst target	$24.45	$29.69
Target upside	+39.40%	+20.70%

Growth, profitability & risk

Metric	STVN	NVST
Revenue growth	6.60%	14.40%
Earnings growth	2.90%	130.00%
EPS growth	+2.90%	+130.00%
FCF margin	-4.74%	+7.70%
Operating margin	N/A	9.87%
Profit margin	11.75%	2.41%
ROIC proxy	9.59%	2.21%
Return on equity	9.59%	2.21%
Dividend yield	0.00%	N/A
Beta	0.78	0.89
Debt/equity	29.43	51.61
Current ratio	1.63	2.44
Quick ratio	1.10	1.93

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

STVN max drawdown51.95%

NVST max drawdown25.97%

STVN max wkly drop17.76%

NVST max wkly drop11.64%

5Y risk snapshot

STVN max drawdown61.94%

NVST max drawdown71.00%

STVN max wkly drop23.75%

NVST max wkly drop15.22%

10Y risk snapshot

STVN max drawdown61.94%

NVST max drawdown71.00%

STVN max wkly drop23.75%

NVST max wkly drop39.19%

Performance metrics by period

Period	Metric	STVN	NVST
1Y	Growth	-25.88%	+39.23%
	CAGR	-25.90%	+39.26%
	Sharpe ratio	-0.45	0.93
	Max drawdown	51.95%	25.97%
	Max daily drop	9.86%	10.27%
	Max wkly drop	17.76%	11.64%
5Y	Growth	-9.48%	-39.42%
	CAGR	-2.00%	-9.54%
	Sharpe ratio	0.12	-0.22
	Max drawdown	61.94%	71.00%
	Max daily drop	21.59%	10.27%
	Max wkly drop	23.75%	15.22%
10Y	Growth	-9.48%	-7.30%
	CAGR	-2.00%	-1.12%
	Sharpe ratio	0.12	0.06
	Max drawdown	61.94%	71.00%
	Max daily drop	21.59%	23.19%
	Max wkly drop	23.75%	39.19%

Business comparison

Category	STVN	NVST
Company	Stevanato Group S.p.A.	Envista Holdings Corporation
Sector	Healthcare - Drug Containment & Delivery Systems	Healthcare
Industry	N/A	Medical Instruments & Supplies
Core business	Stevanato Group is an Italian industrial conglomerate and global provider of drug containment and delivery systems for the pharmaceutical industry. Stevanato manufactures glass vials (for injectables), prefilled syringes, cartridges, and polymer containers used by pharmaceutical and biotech companies to package vaccines, biologics, specialty drugs, and traditional injectables. Stevanato also provides engineering and automation systems for pharmaceutical packaging lines. Key segments: Biopharmaceutical and Diagnostic Solutions (BDS — glass vials, syringes, drug delivery systems) and Engineering (packaging line automation equipment, inspection systems). Stevanato is listed on NYSE since 2021 and its founding family (Stevanato family) retains a significant stake.	Envista Holdings is a global dental products company spun off from Danaher Corporation in 2019. Envista's portfolio spans: Specialty Products and Technologies (dental implants — Nobel Biocare brand, Ormco clear aligners and orthodontic brackets, and other specialty dental products) and Equipment and Consumables (Kerr dental materials and instruments, DEXIS imaging — digital X-rays, 3D cone beam CT scanners, and imaging software). Envista serves dental practices, dental laboratories, and orthodontic practices globally through a combination of direct sales forces and dealer distribution.
Investor focus	Investors track Stevanato's BDS segment revenue and volume growth (driven by biologic drug and vaccine demand), high-value product (HVP) mix shift (premium coated vials, prefillable syringes providing higher margins versus commodity vials), and engineering backlog (automation line orders from pharma manufacturers).	Investors track Envista's dental implant revenue and market share (Nobel Biocare competing with Straumann, Zimmer Biomet, Dentsply Sirona in implants), orthodontics revenue (Spark clear aligners competing with Align Technology's Invisalign), equipment and consumables revenue, and operating margin improvement from the post-Danaher separation restructuring.

STVN strengths

→Secular growth in biologic drugs drives sustained injectable packaging demand — the rise of biologics, biosimilars, gene therapies, GLP-1 receptor agonists (Ozempic, Wegovy), and vaccines creates growing demand for high-quality glass and polymer containers; injectable drugs require specialized containment solutions that oral drugs do not
→High-value product portfolio (prefillable syringes, cartridges) provides better margins than commodity vials — Stevanato's prefillable syringes and specialty cartridges command premium pricing due to regulatory complexity and the precision manufacturing required; shifting mix toward these products improves gross margins over time
→Integrated manufacturing and engineering capabilities create cross-selling opportunities — Stevanato's ability to supply both the containment system and the packaging line automation equipment to pharma customers provides a differentiated bundled offering

NVST strengths

→Nobel Biocare is a premium dental implant brand with long clinical track record — Nobel Biocare has decades of peer-reviewed clinical data supporting its implant products; dental implants are lifetime restorations where clinical longevity data matters significantly to dentists' brand selection
→Clear aligner market growth benefits Spark (Ormco) — Ormco's Spark clear aligner product participates in the rapidly growing clear aligner market (driven by Align Technology's Invisalign-educated consumer demand); Spark's unique aligner material (TruGEN XR) differentiates from Invisalign
→Post-Danaher operational improvement opportunity — Envista's separation from Danaher created an independent dental company that can optimize its own operations; margin improvement opportunity exists as Envista rationalizes its product portfolio and improves manufacturing efficiency independent of Danaher's conglomerate structure

Risks to watch — STVN

→Commodity glass vial market faces intense pricing competition from Chinese and Indian manufacturers — standard borosilicate glass vials face commodity pricing competition; Stevanato must continuously shift mix toward higher-value products to sustain margins
→Glass vial supply chain disruptions can harm pharmaceutical manufacturing partners — glass vial supply was severely strained during COVID vaccine production; supply constraints damage relationships with pharmaceutical customers who need reliable containment supply
→GLP-1 drug boom creates extraordinary demand but also capacity investment requirements — the rapid growth of GLP-1 injectable drugs (Ozempic, Wegovy, Mounjaro, Zepbound) creates strong demand for prefillable pens and cartridges; Stevanato must invest heavily in capacity to capture this growth, which requires significant capital expenditure

Risks to watch — NVST

→Dental market is experiencing demand headwinds post-COVID — after a strong 2021-2022 dental recovery, dental procedure volumes have moderated; dental implant growth has slowed from elevated post-COVID levels
→Competition in dental implants is intensifying from Straumann, Dentsply, and Zimmer Biomet — dental implant competitors are growing market share; Nobel Biocare must sustain its premium pricing versus lower-cost implant alternatives
→Spark clear aligner faces dominant Invisalign competition — Align Technology's Invisalign has approximately 80% clear aligner market share; competing with Invisalign's brand recognition, doctor training ecosystem, and digital workflow integration is a major commercial challenge for Spark

Frequently asked questions

Prefillable syringes (PFS) are single-use glass or polymer syringes filled with a drug product at the manufacturing stage — the patient or healthcare provider injects the pre-filled drug directly, eliminating the need for manual drawing from a vial. Traditional fill-and-finish: healthcare providers draw a drug from a glass vial into a standard syringe just before administration; this introduces contamination risk (particles, microbes), dosing error risk (wrong volume drawn), and wastage (multi-dose vials must be discarded if contaminated). PFS advantages: standardized dose per syringe (reduces dosing error), reduced contamination risk, drug stability (the syringe primary container is optimized for the specific drug product), convenience (patient can self-inject at home), and reduced wasted drug. Why biologics prefer PFS: biologic drugs (monoclonal antibodies, proteins, peptides like GLP-1 agonists) are highly sensitive to oxidation, particulate contamination, and container interactions; PFS are designed to minimize these interactions; PFS materials (glass or cyclic olefin polymer) are selected based on drug compatibility testing; coated PFS (siliconized internally) reduce protein aggregation; the tight volume control in PFS is essential for potent biologic drugs where even small dose variations matter. Market relevance for Stevanato: PFS are a higher-margin product than commodity vials; demand is growing strongly as biologics (adalimumab, pembrolizumab, ustekinumab) and GLP-1 drugs (semaglutide/Ozempic, tirzepatide/Mounjaro) are all formulated in PFS or autoinjector platforms requiring Stevanato's containers.

AI Prediction SignalNext 5 trading days

Members only

STVN

+2.8%BUY

NVST

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

Related comparisons

NVST vs DHR

Dental Products vs Life Science Instruments